InflaRx (IFRX) Operating Leases (2018 - 2025)
InflaRx (IFRX) posted Operating Leases of $1.0 million for Q4 2025, up 352.9% sequentially from $230781.7 in Q2 2025, and up 21.49% YoY from $860311.2 in Q4 2024.
InflaRx (IFRX) Operating Leases (2018 - 2025) Analysis & Trends
InflaRx has reported Operating Leases for 8 years, with the latest figure at $1.0 million in Q4 2025.
- Quarterly Operating Leases rose 21.49% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 million (up 21.49% YoY) and the FY2025 annual result came in at $1.0 million, up 16.42% from the prior year.
- Operating Leases advanced to $1.0 million in Q4 2025 per IFRX's latest filing, from $230781.7 in the prior quarter.
- Over five years, Operating Leases peaked at $1362.6 billion in Q3 2021 and troughed at $230781.7 in Q2 2025.
- A 5-year average of $136.3 billion and a median of $1.1 million in 2023 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2021 and 2025: Operating Leases soared 947882.36% in 2021, then sank 64.35% in 2025.
- Over 5 years, Operating Leases stood at $1.6 million in 2021, then declined by 15.54% to $1.4 million in 2022, then fell by 12.94% to $1.2 million in 2023, then dropped by 28.61% to $860311.2 in 2024, then rose by 21.49% to $1.0 million in 2025.
- According to Business Quant data, Operating Leases over the past three periods registered $1.0 million, $230781.7, and $860311.2 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.05 Mn |
| Jun 30, 2025 | 230,781.68 |
| Dec 31, 2024 | 860,311.20 |
| Jun 30, 2024 | 647,419.43 |
| Dec 31, 2023 | 1.21 Mn |
| Jun 30, 2023 | 886,994.25 |
| Dec 31, 2022 | 1.38 Mn |
| Jun 30, 2022 | 1.25 Mn |
| Dec 31, 2021 | 1.64 Mn |
| Sep 30, 2021 | 1,362.59 Bn |
| Dec 31, 2020 | 666,538.91 |
| Sep 30, 2020 | 143.74 Mn |
| Jun 30, 2020 | 224.30 Mn |
| Mar 31, 2020 | 270.99 Mn |
| Dec 31, 2019 | 936,369.41 |
| Jun 30, 2019 | 1.11 Mn |
| Dec 31, 2018 | 833,986.41 |